InventisBio Co., Limited
InventisBio is a Shanghai-based company listed on the STAR Market (SSE: 688382). Its KRAS G12C inhibitor garsorasib (D-1553) was approved in China in November 2024, and its oral candidate D-2570 met the primary endpoint of a Phase 3 study in plaque psoriasis.
| Headquarters | Shanghai, China |
|---|---|
| Listing | SSE:688382 |
| Lead asset / stage | garsorasib (D-1553) Approved — China |
| Latest event | InventisBio reported that the D-2570 Phase 3 plaque psoriasis study met its primary endpoint. |